Antibody-drug conjugates(ADCs) are novel antineoplastics that combine the high targeting specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule toxins. By selectively delivering cytotoxic payloads to tumor cells, ADCs achieve effective tumor cell killing while minimizing damage to healthy cells and reducing systemic toxicity. These innovative agents, often referred to as “biological missile”, are leading a new era in targeted cancer therapy.Although three generations of ADCs have been applied to cancer treatment, further optimization of the components of ADCs is still required to address challenges such as stability, cytotoxicity, and drug resistance. This article summarizes the approved ADCs and those under clinical research, outlines innovative directions for next-generation ADCs, to provide insights for advancing research and development of novel cancer treatments using ADC technology.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |